Last reviewed · How we verify

Poisoning by iron AND/OR its compounds — Treatment Landscape & Competitive Intelligence

Poisoning by iron AND/OR its compounds (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Poisoning by iron AND/OR its compounds, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Desferal DEFEROXAMINE Mitem Pharma Iron Chelator Deoxyhypusine hydroxylase 1968-01-01
desferrioxamine desferrioxamine Brigham and Women's Hospital Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Brigham and Women's Hospital · 1 drug in Poisoning by iron AND/OR its compounds
  2. Mitem Pharma · 1 drug in Poisoning by iron AND/OR its compounds

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Poisoning by iron AND/OR its compounds:

Cite this brief

Drug Landscape (2026). Poisoning by iron AND/OR its compounds — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/poisoning-by-iron-and-or-its-compounds. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing